Seeking Alpha

Prohost Biotech

View as an RSS Feed
View Prohost Biotech's Comments BY TICKER:
Latest  |  Highest rated
  • Are You Betting Too Much On Theravance? [View article]
    Such formidable debates do not exist anywhere except at Seeking Alpha stage. Such discussions are very revealing and helpful for investors.
    Apr 18 09:23 AM | Likes Like |Link to Comment
  • Prosensa: Back Into The Limelight [View article]
    Thanks Techcapital
    Mar 19 02:31 PM | Likes Like |Link to Comment
  • Investing In The Future: Illumina [View article]
    Excellent articles and very useful comments. You almost said it all. Our 1st target for ILMN was $150 and we did not change it when the stock crossed it. Our target for 2016 is more than double the 1st target. Important for investors is to not miss the future rallies in what we reiterated it is the engine of the biotech industry.
    Mar 13 05:31 PM | 1 Like Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    Jakafi results on polycythemia vera were published to day. We advise having a look. Also good luck for Geron. Still the title of this article seems to have said it all.
    Mar 7 07:37 AM | Likes Like |Link to Comment
  • 3 Reasons To Stay Far Away From Synta Pharmaceuticals Stock [View article]
    Stock is trading over $6 now! There is reason for this, but it is scientific. Did you read the most recent news???
    Mar 2 06:53 AM | Likes Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    FACT: This discussion began on November 12 2013. The stock was trading at less than $39. The last posting was on Dec. 17, INCY had already added $7. Today is February 12, 2014, i.e.., less than three months later, the stock is trading over $69, adding $30 to stock price during this discussion.
    Feb 13 06:23 AM | 1 Like Like |Link to Comment
  • The Hep C Race Is Heating Up: AbbVie Vs. Gilead [View article]
    That's true, not to forget ENTA, the brain behind the main drug used by ABBV.
    Feb 10 08:18 AM | 3 Likes Like |Link to Comment
  • Pharmacyclics: Product Pipeline Overshadows Stock Market Influence [View article]
    A long-term growth, i.e., a sustained continuous rally for years to come. Companies like this one continue to evolve with the unprecedented scientific evolution. They are fishers of substance in the knowledge that inspires them to design better and better treatments until they reach their goal. Their goal is turning some deadly diseases into chronic diseases and offering cures for others, which is what is expected from the human brain's unlimited capability. Bottom line, PCYC will continue to rally as long as the firm continues to innovate. We have no reason to believe it will not continue to outperform.
    Feb 10 01:04 AM | Likes Like |Link to Comment
  • Agenus Offers An Investment Opportunity [View article]
    Adam is a great guy. Let him do whatever he wishes as long as he is happy and makes some people around him and following him happy too . Those who got hurt by what he wrote or said are rather more frustrated of themselves than hurt by Adam. They know well that their anger against the man is in fact against their picks failure and against themselves because they failed to select better firms. Adam, they know cannot by himself paralyze a stock and kill its giant company unless the giant is no giant but a victim of a morbid obesity.
    Feb 8 08:23 PM | Likes Like |Link to Comment
  • Is There Still Room To Profit With Halozyme? [View article]
    Great follow up on your investments. We are talking about the commentators, not the author of the article who does not own any HALO. The article fair and balanced and gives the reader enough knowledge about the firm's technology and pipeline. It omitted unnecessary details that interested readers can get through research engines that are filling the place.
    Feb 5 12:22 PM | Likes Like |Link to Comment
  • Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products [View article]
    Great work. nearest to reality estimates. As one of two firms currently topping the Top-Tier biotech industry, Amgen has been underestimated and undervalued for long enough to box many investors in the zone of pessimism, while giving others one of the best opportunities to more than double their investment value. We believe that the profit generated from betting on the wounded king of biotech industry in the past couple of years is the beginning, rather than the end of the road for a monstrous rallying in AMGN. This is fair and honest analysis.
    Jan 29 06:40 AM | Likes Like |Link to Comment
  • Arena Pharmaceuticals - Why I Believe It Is The Next Major Biotech [View article]
    We don't know what these doctors believe, but the truth is that obesity is a real problem that should be taken care of. It is surely not just bad behavior, bad habits, or food addiction, but a lot more is in it that is sufficient to classify some cases of obesity and morbid obesity as diseases.

    The feeling of satiety is seen to take a lot of weight off patients’ bodies and researchers are discovering pathways of satiety in the distal intestines in what is called the ileal brake. Activation of the ileal brake has proven to release mediators that cause satiety and weight loss. It was found that success of the bariatric stomach surgeries in causing a sustained weight loss was not caused by the mechanical reason only, but also by chemical pathways. This ileal brake seems to be behind the successful sustained weight loss following the bariatric surgery. It was found that the undigested food smuggled into the intestine following the stomach bypass surgery was mainly the outcome of the activation of the ileal brake, leading to the release of the mediators of satiety, hence to the sustained weight loss.

    Recently, researchers at Boston Children's Hospital have identified a genetic cause of severe obesity that, though rare, might have raised questions about weight gain and energy use in the general obese population. The research, which was published in the journal Science of July 19, 2013, involved genetic surveys of several groups of obese humans and experiments in mice. The researchers spotted a mutation in mice gene known as Mrap2 that has a human counterpart (MRAP2). The mice with the mutation seem not able to burn the food and to gain more weight than usual. The researchers found similar mutations in a cohort of obese humans.

    Mice without Mrap2 gained weight faster than the controls. Their appetites continued to increase as time passed and they continued to gain more weight than the controls, even when held to the same diet.

    The researchers found four mutations in the human equivalent of Mrap2 among 500 people, all in patients with severe, early-onset obesity. The researchers suspect that other mutations in the gene might occur more commonly and might interact with other mutations and environmental factors to cause more common forms of obesity. They are looking forward to studying additional populations of obese people and further exploring how the gene alters energy balance.

    So, obesity is not all instigated by the character, behavior, or addition to eating by the obese people. It has been more and more considered the outcome of pathological pathways.

    Until they investigate all these pathways and their origins, we will surely need drugs that cause satiety. According to those who have experienced Arena’s drug Belvq, it seems that the drug has caused satiety and weight loss. It worked.
    Jan 21 06:25 PM | Likes Like |Link to Comment
  • Illumina And The Future Of Life Sciences [View article]
    Sorry not to unswear you on time. We had a target. It was reached and we raised it. The raised target was reached and we raised it again and continued to raise targets until we decided to write that we have no plans selling this firm because without it there will be no biological or clinical revolution. When you asked your question the stock was trading around $78. To day it is trading ahead of the market at around $133.
    Jan 17 08:45 AM | Likes Like |Link to Comment
  • Intercept Liver Drug Is A Game Changer For The Biotech Industry [View article]
    If you don't believe in not giving a drug that would save condemned people because it might raise the level of their cholesterol good for you and the patients who might follow your advice. Everybody is entitled to his opinion and there is no point in diffusing your anger and frustration through accusing and insulting those who don't agree with your logic.
    Jan 12 11:10 PM | Likes Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    you would be correct if imetelstat is in final phase trial and the results confirm the abstract and the drug is expected to be approved tomorrow. If imetelstat will move forward in clinical trials with promising results it would take at least 5-6 years for the drug to reach the market, during which time INCY, through Jakafi for myelofibrosis (MF) or other indications plus the rest of the pipeline would have tripled in value. All that has nothing to o with imetelstat success or failure. That's what we tried to insinuate in the article.
    Dec 14 07:44 PM | Likes Like |Link to Comment